Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 May 2012

McArthur Grant A, Puzanov Igor, Amaravadi Ravi, Ribas Antoni, Chapman Paul, Kim Kevin B, Sosman Jeffrey A, Lee Richard J, Nolop Keith, Flaherty Keith T, Callahan Jason, Hicks Rodney J

Abstract excerpt

PURPOSE: Imaging with [(18)F]fluorodeoxyglucose (FDG) -positron emission tomography (PET) allows early recognition of a response to agents that target key driver mutations in human cancer. We aimed to determine the metabolic response rate to vemurafenib in patients with advanced BRAF-mutant melanoma. PATIENTS AND METHODS: Baseline and day 15 FDG-PET was evaluated in 31 patients with advanced melanoma treated in a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Confidence Intervals
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Early Diagnosis

Share to Fluorodeoxyglucose F18

Share to Maximum Tolerated Dose

Share to Monitoring, Physiologic

Share to Positron-Emission Tomography

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 22454415
DOI: 10.1200/JCO.2011.39.1938
PMCID: PMC5950495

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.PMID 22454415Read ↗

Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma.Semantic proximity Read ↗

(18)F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma.Semantic proximity Read ↗

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.Semantic proximity Read ↗

Heterogeneity of CD8 T-Cell Changes in Advanced Melanomas After Initiation of ImmunotherapySemantic proximity Read ↗

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.Semantic proximity Read ↗

Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.Semantic proximity Read ↗

Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study.Semantic proximity Read ↗

A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma.Semantic proximity Read ↗

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.Semantic proximity Read ↗

Development of [11C]vemurafenib employing a carbon-11 carbonylative Stille coupling and preliminary evaluation in mice bearing melanoma tumor xenografts.Semantic proximity Read ↗

[Efficacy and safety of vemurafenib in the treatment of BRAF(V600E)-mutated Erdheim-Chester disease].Semantic proximity Read ↗

Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.